Zealand Pharma: shares up after Bryan Garnier raises target.
(CercleFinance.com) - Zealand Pharma shares are up on Friday after Bryan garnier raised its target price for the stock from 200 Danish kronor to 210 Danish kronor, saying the Danish biotech firm is "stronger than ever.
"
In a note to clients Bryan Garnier analysts said that Zealand is now opening "a new chapter in its history" with the success of gastrointestinal drug glepaglutide in phase II.
The broker notes that the pipeline has three projects moving forward, of which two are ready for phase III trials.
"In conclusion, Zealand has today more mature and diversified assets than ever," BG wrote, maintaining its "buy" rating on the stock.
The shares are currently up 1.2% at 128.5 Danish kronor, their highest level in a year. The shares have risen by over 20% year-to-date.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"
In a note to clients Bryan Garnier analysts said that Zealand is now opening "a new chapter in its history" with the success of gastrointestinal drug glepaglutide in phase II.
The broker notes that the pipeline has three projects moving forward, of which two are ready for phase III trials.
"In conclusion, Zealand has today more mature and diversified assets than ever," BG wrote, maintaining its "buy" rating on the stock.
The shares are currently up 1.2% at 128.5 Danish kronor, their highest level in a year. The shares have risen by over 20% year-to-date.
Copyright (c) 2017 CercleFinance.com. All rights reserved.